Vericel (VCEL) Competitors $56.50 +1.55 (+2.82%) (As of 12/20/2024 05:17 PM ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends VCEL vs. QGEN, ITCI, ROIV, ASND, RVMD, LNTH, NUVL, BPMC, LEGN, and ELANShould you be buying Vericel stock or one of its competitors? The main competitors of Vericel include Qiagen (QGEN), Intra-Cellular Therapies (ITCI), Roivant Sciences (ROIV), Ascendis Pharma A/S (ASND), Revolution Medicines (RVMD), Lantheus (LNTH), Nuvalent (NUVL), Blueprint Medicines (BPMC), Legend Biotech (LEGN), and Elanco Animal Health (ELAN). These companies are all part of the "pharmaceutical products" industry. Vericel vs. Qiagen Intra-Cellular Therapies Roivant Sciences Ascendis Pharma A/S Revolution Medicines Lantheus Nuvalent Blueprint Medicines Legend Biotech Elanco Animal Health Qiagen (NYSE:QGEN) and Vericel (NASDAQ:VCEL) are both medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their profitability, earnings, institutional ownership, community ranking, analyst recommendations, risk, dividends, media sentiment and valuation. Does the MarketBeat Community favor QGEN or VCEL? Vericel received 100 more outperform votes than Qiagen when rated by MarketBeat users. Likewise, 61.77% of users gave Vericel an outperform vote while only 60.88% of users gave Qiagen an outperform vote. CompanyUnderperformOutperformQiagenOutperform Votes24960.88% Underperform Votes16039.12% VericelOutperform Votes34961.77% Underperform Votes21638.23% Do institutionals and insiders believe in QGEN or VCEL? 70.0% of Qiagen shares are owned by institutional investors. 9.0% of Qiagen shares are owned by insiders. Comparatively, 5.2% of Vericel shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term. Which has more volatility and risk, QGEN or VCEL? Qiagen has a beta of 0.35, indicating that its share price is 65% less volatile than the S&P 500. Comparatively, Vericel has a beta of 1.71, indicating that its share price is 71% more volatile than the S&P 500. Is QGEN or VCEL more profitable? Qiagen has a net margin of 4.73% compared to Vericel's net margin of 1.56%. Qiagen's return on equity of 13.43% beat Vericel's return on equity.Company Net Margins Return on Equity Return on Assets Qiagen4.73% 13.43% 8.10% Vericel 1.56%1.48%0.96% Which has higher earnings and valuation, QGEN or VCEL? Qiagen has higher revenue and earnings than Vericel. Qiagen is trading at a lower price-to-earnings ratio than Vericel, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioQiagen$1.97B5.18$341.30M$0.39114.54Vericel$226.84M12.29-$3.18M$0.06941.67 Does the media prefer QGEN or VCEL? In the previous week, Vericel had 4 more articles in the media than Qiagen. MarketBeat recorded 9 mentions for Vericel and 5 mentions for Qiagen. Vericel's average media sentiment score of 0.74 beat Qiagen's score of 0.47 indicating that Vericel is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Qiagen 2 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Vericel 2 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Do analysts rate QGEN or VCEL? Qiagen presently has a consensus price target of $51.88, suggesting a potential upside of 16.13%. Vericel has a consensus price target of $61.14, suggesting a potential upside of 8.22%. Given Qiagen's higher possible upside, analysts clearly believe Qiagen is more favorable than Vericel.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Qiagen 0 Sell rating(s) 3 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 2.67Vericel 0 Sell rating(s) 0 Hold rating(s) 6 Buy rating(s) 1 Strong Buy rating(s) 3.14 SummaryQiagen and Vericel tied by winning 9 of the 18 factors compared between the two stocks. Ad Crypto Swap ProfitsURGENT: This Altcoin Opportunity Won’t Wait – Act NowCrypto has officially entered the "banana zone" – that wild phase where prices can 1000x in days. It happens like clockwork every 4 years, during the December to February window of a Bitcoin halving year. This is where fortunes are made – often LITERALLY overnight.>> Register for the Workshop Now Get Vericel News Delivered to You Automatically Sign up to receive the latest news and ratings for VCEL and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart VCEL vs. The Competition Export to ExcelMetricVericelBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$2.79B$2.94B$5.12B$9.07BDividend YieldN/A1.90%4.91%4.22%P/E Ratio941.8246.7391.3417.19Price / Sales12.29411.851,117.70116.80Price / Cash3,286.81182.1042.6437.86Price / Book11.953.894.794.78Net Income-$3.18M-$42.21M$120.07M$225.60M7 Day Performance-1.69%-2.14%-1.90%-1.23%1 Month Performance-0.37%4.21%11.45%3.37%1 Year Performance59.15%18.40%30.63%16.58% Vericel Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)VCELVericel1.4381 of 5 stars$56.50+2.8%$61.14+8.2%+66.0%$2.79B$226.84M941.82300Analyst ForecastQGENQiagen3.512 of 5 stars$45.46+0.1%$51.15+12.5%+3.1%$10.37B$1.97B117.035,967ITCIIntra-Cellular Therapies4.0477 of 5 stars$84.70+2.0%$97.23+14.8%+27.8%$8.98B$612.78M-95.91560ROIVRoivant Sciences3.0007 of 5 stars$12.07+1.9%$17.93+48.5%+16.2%$8.79B$129.13M2.10860Insider TradeASNDAscendis Pharma A/S3.1363 of 5 stars$135.90+4.6%$191.77+41.1%+12.6%$8.24B$327.43M-16.52640RVMDRevolution Medicines4.5486 of 5 stars$44.86-0.3%$63.67+41.9%+71.5%$7.55B$11.58M-12.54443Insider TradeLNTHLantheus4.3807 of 5 stars$94.94+2.1%$130.00+36.9%+53.4%$6.60B$1.50B15.42834Analyst ForecastNUVLNuvalent2.1944 of 5 stars$86.67-0.2%$112.60+29.9%+16.9%$6.16BN/A-25.0340Insider TradeNews CoveragePositive NewsBPMCBlueprint Medicines2.5701 of 5 stars$95.51+2.5%$122.11+27.8%+7.2%$6.07B$434.42M-45.28640Insider TradeLEGNLegend Biotech1.5523 of 5 stars$33.17-5.6%$81.54+145.8%-43.2%$6.06B$520.18M-36.971,800ELANElanco Animal Health3.7792 of 5 stars$12.19+0.7%$16.75+37.4%-17.0%$6.03B$4.45B30.259,300 Related Companies and Tools Related Companies QGEN Competitors ITCI Competitors ROIV Competitors ASND Competitors RVMD Competitors LNTH Competitors NUVL Competitors BPMC Competitors LEGN Competitors ELAN Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:VCEL) was last updated on 12/21/2024 by MarketBeat.com Staff From Our PartnersAmazon coin set to soar 25X – starting December 16th?This tiny 3-cent crypto just partnered with one of the biggest companies in the world… Amazon. And one team...True Market Insiders | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001."Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredTop Picks for Trump’s Pro-Crypto AmericaCoins Set to Soar with a Pro-Crypto White House President-Elect Donald Trump is reported to be holding over...Crypto 101 Media | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Vericel Co. Please log in to your account or sign up in order to add this asset to your watchlist. Share Vericel With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free VCEL Stock Alerts